Invivo Therapeutics (NVIV) Getting Somewhat Critical Media Coverage, Analysis Finds
Headlines about Invivo Therapeutics (NASDAQ:NVIV) have been trending somewhat negative recently, Accern Sentiment reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Invivo Therapeutics earned a media sentiment score of -0.05 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.618614945388 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Invivo Therapeutics (NASDAQ:NVIV) remained flat at $$0.69 during trading on Friday. The stock had a trading volume of 128,090 shares, compared to its average volume of 359,815. Invivo Therapeutics has a twelve month low of $0.60 and a twelve month high of $4.95. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $23.54, a PE ratio of -0.81 and a beta of 3.21.
Invivo Therapeutics (NASDAQ:NVIV) last posted its earnings results on Monday, October 30th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.06). equities analysts anticipate that Invivo Therapeutics will post -0.81 EPS for the current fiscal year.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.